These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38250029)

  • 1. Contemporary review on pediatric hypertrophic cardiomyopathy: insights into detection and management.
    Shafqat A; Shaik A; Koritala S; Mushtaq A; Sabbah BN; Nahid Elshaer A; Baqal O
    Front Cardiovasc Med; 2023; 10():1277041. PubMed ID: 38250029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy.
    Maron MS
    J Cardiovasc Magn Reson; 2012 Feb; 14(1):13. PubMed ID: 22296938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 5. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: Current state of the art.
    Kamal MU; Riaz IB; Janardhanan R
    Cardiol J; 2016; 23(3):250-63. PubMed ID: 27064795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.
    Axelsson Raja A; Farhad H; Valente AM; Couce JP; Jefferies JL; Bundgaard H; Zahka K; Lever H; Murphy AM; Ashley E; Day SM; Sherrid MV; Shi L; Bluemke DA; Canter CE; Colan SD; Ho CY
    Circulation; 2018 Aug; 138(8):782-792. PubMed ID: 29622585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy.
    Maron MS
    J Cardiovasc Transl Res; 2009 Dec; 2(4):415-25. PubMed ID: 20560000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.
    Rodrigues JC; Rohan S; Ghosh Dastidar A; Harries I; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Radiol; 2017 Mar; 27(3):1125-1135. PubMed ID: 27368925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late gadolinium enhancement entropy as a new measure of myocardial tissue heterogeneity for prediction of adverse cardiac events in patients with hypertrophic cardiomyopathy.
    Gu ZY; Qian YF; Chen BH; Wu CW; Zhao L; Xue S; Zhao L; Wu LM; Wang YY
    Insights Imaging; 2023 Aug; 14(1):138. PubMed ID: 37603140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap?
    Nakano SJ; Menon SC
    Prog Pediatr Cardiol; 2018 Jun; 49():31-37. PubMed ID: 31097901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy.
    Fahmy AS; Rowin EJ; Jaafar N; Chan RH; Rodriguez J; Nakamori S; Ngo LH; Pradella S; Zocchi C; Olivotto I; Manning WJ; Maron M; Nezafat R
    JACC Cardiovasc Imaging; 2024 Jan; 17(1):16-27. PubMed ID: 37354155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
    Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
    Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
    JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.